Triasima Portfolio Management inc. Acquires 10,991 Shares of Natera, Inc. $NTRA

Triasima Portfolio Management inc. bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,991 shares of the medical research company’s stock, valued at approximately $4,543,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trust Co. of Vermont acquired a new stake in Natera in the second quarter valued at $26,000. Reflection Asset Management purchased a new stake in Natera during the 4th quarter worth about $29,000. Elevation Wealth Partners LLC purchased a new stake in Natera during the 2nd quarter worth about $30,000. Continuum Advisory LLC acquired a new position in shares of Natera during the 2nd quarter worth about $33,000. Finally, International Assets Investment Management LLC boosted its position in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $404.79 on Friday. Natera, Inc. has a 1-year low of $178.01 and a 1-year high of $437.41. The stock has a market cap of $58.35 billion, a PE ratio of -297.64 and a beta of 1.50. The firm has a fifty day moving average price of $356.78 and a 200 day moving average price of $274.42.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter last year, the company posted ($0.74) earnings per share. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. As a group, equities analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on NTRA. TD Cowen increased their price objective on Natera from $340.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday. BTIG Research boosted their target price on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Barclays upped their price target on Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Finally, Robert W. Baird set a $348.00 price target on shares of Natera in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $368.69.

Insider Transactions at Natera

In related news, CEO Steven Chapman sold 1,273 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $413.31, for a total transaction of $526,143.63. Following the transaction, the chief executive officer owned 96,926 shares in the company, valued at $40,060,485.06. This trade represents a 1.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00. Following the transaction, the insider directly owned 106,914 shares in the company, valued at approximately $44,285,917.08. This trade represents a 2.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 52,985 shares of company stock valued at $16,119,137 over the last quarter. Company insiders own 5.05% of the company’s stock.

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.